Phreesia (NYSE:PHR) Price Target Raised to $30.00 at KeyCorp

Phreesia (NYSE:PHR) had its target price raised by investment analysts at KeyCorp from $28.00 to $30.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 5.56% from the stock’s previous close.

PHR has been the topic of several other reports. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $24.00 to $32.00 in a research report on Wednesday. Robert W. Baird lowered their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, Truist Financial boosted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $30.64.

Phreesia Stock Up 5.3 %

Shares of NYSE PHR opened at $28.42 on Wednesday. The business has a 50-day moving average price of $22.70 and a 200 day moving average price of $22.57. The stock has a market cap of $1.65 billion, a PE ratio of -19.33 and a beta of 0.94. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia has a 52-week low of $17.07 and a 52-week high of $29.16.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.58) earnings per share. Equities research analysts forecast that Phreesia will post -1.16 earnings per share for the current year.

Insider Activity

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $20.93, for a total transaction of $532,605.71. Following the completion of the transaction, the senior vice president now owns 93,470 shares of the company’s stock, valued at $1,956,327.10. This represents a 21.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Chaim Indig sold 3,089 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $64,961.67. Following the transaction, the chief executive officer now directly owns 1,220,647 shares in the company, valued at approximately $25,670,206.41. This represents a 0.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,703 shares of company stock worth $2,343,541 over the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently added to or reduced their stakes in the company. Trust Point Inc. increased its position in shares of Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock worth $408,000 after acquiring an additional 607 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in Phreesia by 3.2% during the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares during the period. Rhumbline Advisers increased its holdings in Phreesia by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock valued at $1,741,000 after purchasing an additional 853 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in shares of Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after purchasing an additional 1,120 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.